Nano Dimension defends $890M Infinite Epigenetics deal against Murchinson criticism

Corporate Action
โดย Seeking Alpha·Read original
Summary · why it matters

Nano Dimension and Infinite Epigenetics issued a joint shareholder update defending their proposed $890 million business combination after activist investor Murchinson criticized the deal. Nano Dimension said it reviewed Murchinson's recent letter and noted that final terms are still being negotiated, while emphasizing that Infinite Epigenetics is built on operating businesses, a CLIA-certified methylation laboratory, and defensible proprietary assets. Murchinson, which holds about 7.4% of Nano Dimension's outstanding shares, called the transaction a poor business decision inconsistent with the understanding on which Nano raised capital. The board selected Infinite Epigenetics from a rigorous review of roughly 20 companies as its top growth opportunity, and the deal follows years of tension that included a rejected director replacement bid earlier this year and a 2022 buyout proposal valuing Nano at approximately $995 million.

Impact on stocks 1

Information Technology▲ · 1 stocks
Nano Dimension Ltd
NNDM
± MixedCapitalrelevance

Nano Dimension defends its $890M acquisition of Infinite Epigenetics against activist criticism; deal terms still being negotiated, outcome uncertain.

Off-coverage companies 2

Infinite EpigeneticsPrivate± Mixed
Capitalrelevance

Infinite Epigenetics is the target in the proposed $890M business combination; deal faces activist opposition but is defended by Nano Dimension.

Murchinson LtdPrivate± Mixed
Capitalrelevance

Murchinson is the activist investor criticizing the deal; its 7.4% stake and opposition create uncertainty but no direct impact on Murchinson itself.

© 2026 MarketDXNews